Retracted: Prognostic Comparison between cTACE and H101-TACE in Unresectable Hepatocellular Carcinoma (HCC): A Propensity-Score Matching Analysis

Retracted: Prognostic Comparison between cTACE and H101-TACE in Unresectable Hepatocellular Carcinoma (HCC): A Propensity-Score Matching Analysis

Bibliographic Details
Main Author:	Applied Bionics and Biomechanics
Format:	Article
Language:	English
Published:	Hindawi Limited 2023-01-01
Series:	Applied Bionics and Biomechanics
Online Access:	http://dx.doi.org/10.1155/2023/9813798

Similar Items

The Role of Conventional TACE (cTACE) and DEBIRI-TACE in Colorectal Cancer Liver Metastases
by: Thomas J. Vogl, et al.
Published: (2022-03-01)

Single medium-sized hepatocellular carcinoma treated with sequential conventional transarterial chemoembolization (cTACE) and microwave ablation at 4 weeks versus cTACE alone: a propensity score
by: Zi-yi Zhu, et al.
Published: (2022-06-01)

Vessels That Encapsulate Tumor Clusters (VETC) Predict cTACE Response in Hepatocellular Carcinoma
by: Lin C, et al.
Published: (2023-03-01)

Outcome of conventional transarterial chemoembolization (cTACE) in the management of spontaneously ruptured hepatocellular carcinoma
by: Yashwant Patidar, et al.
Published: (2019-04-01)

Comparing the effectiveness and safety of Sorafenib plus TACE with Apatinib plus TACE for treating patients with unresectable hepatocellular carcinoma: a multicentre propensity score matching study
by: Liang Yin, et al.
Published: (2023-05-01)

Efficacy of adjuvant TACE on the prognosis of patients with HCC after hepatectomy: a multicenter propensity score matching from China
by: Zhao Wu, et al.
Published: (2023-04-01)

Combination therapy of sorafenib and TACE for unresectable HCC: a systematic review and meta-analysis.
by: Lei Liu, et al.
Published: (2014-01-01)

Combined therapy with conventional trans-arterial chemoembolization (cTACE) and microwave ablation (MWA) for hepatocellular carcinoma >3–<5 cm
by: Mohamed M. A. Zaitoun, et al.
Published: (2021-01-01)

TACE versus TACE + entecavir versus TACE + tenofovir in the treatment of HBV associated hepatocellular carcinoma
by: Haohao Lu, et al.
Published: (2023-03-01)

Comparison of local tumor control in patients with HCC treated with SBRT or TACE: a propensity score analysis
by: Dominik Bettinger, et al.
Published: (2018-08-01)

Correction to: Balloon occluded TACE (B-TACE) vs DEM-TACE for HCC: a single center retrospective case control study
by: Pierleone Lucatelli, et al.
Published: (2021-07-01)

Efficacy and safety analysis of TACE + Donafenib + Toripalimab versus TACE + Sorafenib in the treatment of unresectable hepatocellular carcinoma: a retrospective study
by: Haohao Lu, et al.
Published: (2023-10-01)

Development of TACE Refractoriness Scores in Hepatocellular Carcinoma
by: Li Chen, et al.
Published: (2021-03-01)

CT-radiomics and clinical risk scores for response and overall survival prognostication in TACE HCC patients
by: Simon Bernatz, et al.
Published: (2023-01-01)

DEB-TACE with irinotecan versus C-TACE for unresectable intrahepatic cholangiocarcinoma: a prospective clinical study
by: Junxiao Wang, et al.
Published: (2023-01-01)

TACE Plus Lenvatinib Versus TACE Plus Sorafenib for Unresectable Hepatocellular Carcinoma With Portal Vein Tumor Thrombus: A Prospective Cohort Study
by: Biao Yang, et al.
Published: (2021-12-01)

Identify optimal HAP series scores for unresectable HCC patients undergoing TACE plus sorafenib: A Chinese multicenter observational study
by: Yejing Zhu, et al.
Published: (2023-01-01)

Prognostic efficacy and prognostic factors of TACE plus TKI with ICIs for the treatment of unresectable hepatocellular carcinoma: A retrospective study
by: Ziqiang Han, et al.
Published: (2022-12-01)

Preliminary outcomes of DEB-TACE loaded with raltitrexed in the treatment of unresectable or recurrent hepatocellular carcinoma
by: Yonghua Bi, et al.
Published: (2023-02-01)

Evaluation of D-TACE combined with endovascular brachytherapy for HCC with MPVTT
by: Wei Huang, et al.
Published: (2022-08-01)

Efficacy and Safety of TACE Combined With Lenvatinib Plus PD-1 Inhibitors Compared With TACE Alone for Unresectable Hepatocellular Carcinoma Patients: A Prospective Cohort Study
by: Shuping Qu, et al.
Published: (2022-04-01)

Unresectable intrahepatic cholangiocarcinoma: TARE or TACE, which one to choose?
by: Maria Adriana Cocozza, et al.
Published: (2023-10-01)

Idarubicin‐Loaded DEB‐TACE plus Lenvatinib versus Lenvatinib for patients with advanced hepatocellular carcinoma: A propensity score‐matching analysis
by: Wenzhe Fan, et al.
Published: (2023-01-01)

Efficacy Of Apatinib In Transcatheter Arterial Chemoembolization (TACE) Refractory Intermediate And Advanced-Stage Hepatocellular carcinoma：A Propensity Score Matching Analysis
by: Qiu Z, et al.
Published: (2019-11-01)

TACE and conformal radiotherapy vs. TACE alone for hepatocellular carcinoma: A randomised controlled trial
by: Cyrille Féray, et al.
Published: (2023-04-01)

The role of scheduled second TACE in early-stage hepatocellular carcinoma with complete response to initial TACE
by: Jung Hee Kim, et al.
Published: (2017-03-01)

Efficacy and safety of TACE combined with lenvatinib and PD‐1 inhibitors for unresectable recurrent HCC: A multicenter, retrospective study
by: Wei‐Jun Wang, et al.
Published: (2023-05-01)

TACE Combined with Lenvatinib and Camrelizumab for Unresectable Multiple Nodular and Large Hepatocellular Carcinoma (>5 cm)
by: Zhanwang Xiang MD, et al.
Published: (2023-09-01)

TACE-Sorafenib With Thermal Ablation Has Survival Benefits in Patients With Huge Unresectable Hepatocellular Carcinoma
by: Ying Wu, et al.
Published: (2020-07-01)

CXCL1 and CXCL6 Are Potential Predictors for HCC Response to TACE
by: Maximilian N. Kinzler, et al.
Published: (2023-03-01)

A Novel Nomogram for Predicting the Overall Survival in Patients with Unresectable HCC after TACE plus Hepatic Arterial Infusion Chemotherapy
by: Baojiang Liu, et al.
Published: (2023-08-01)

The Efficacy of TACE Combined With Lenvatinib Plus Sintilimab in Unresectable Hepatocellular Carcinoma: A Multicenter Retrospective Study
by: Fei Cao, et al.
Published: (2021-12-01)

Trans-arterial chemo-embolization (TACE), with either lipiodol (traditional TACE) or drug-eluting microspheres (precision TACE, pTACE) in the treatment of hepatocellular carcinoma: efficacy and safety results from a large mono-institutional analysis
by: Marmorale Cristina, et al.
Published: (2010-12-01)

Transarterial Chemoembolization (TACE) Plus Sorafenib Compared to TACE Alone in Transplant Recipients with Hepatocellular Carcinoma: An Institution Experience
by: Maen Abdelrahim, et al.
Published: (2022-01-01)

Impact of preoperative transcatheter arterial chemoembolization (TACE) on postoperative long-term survival in patients with nonsmall hepatocellular carcinoma: a propensity score matching analysis
by: Run Hu, et al.
Published: (2024-02-01)

Impact of preoperative TACE on incidences of microvascular invasion and long‐term post‐hepatectomy survival in hepatocellular carcinoma patients: A propensity score matching analysis
by: Yun Yang, et al.
Published: (2021-03-01)

Optimal interventional treatment for liver cancer: HAIC, TACE or iTACE?
by: Naijian Ge, et al.
Published: (2023-05-01)

The Feasibility of TACE Combined with TKIs Plus PD-1 Antibody for Advanced HCC
by: Sun T, et al.
Published: (2023-03-01)

Outcomes and prognostic factors in initially unresectable hepatocellular carcinoma treated using conversion therapy with lenvatinib and TACE plus PD-1 inhibitors
by: Xingzhi Li, et al.
Published: (2023-01-01)

Effectiveness of c-TACE Combined With Sorafenib Versus c-TACE Monotherapy in Advanced Hepatocellular Carcinoma: A Retrospective Study
by: Shanshan Liu, et al.
Published: (2023-02-01)